Instil Bio, Inc. (TIL)
Nasdaq · Healthcare · Biotechnology
$6.95−3.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $47.1M
- 52-week range
- $5.67 – $21.98
- 52-week change
- −61.14%
- EPS (trailing)
- −$4.43
Fiscal year to Dec 2025
- Net income
- −$71.4M
- Diluted EPS
- −$10.70
From the company’s annual report on SEC EDGAR.
About Instil Bio, Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Headquarters: Dallas, United States · 17 employees · instilbio.com